Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YSCH-01 in Advanced Solid Tumors and NSCLC
NCT07793500Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant L-IFN adenovirus in non-small cell lung cancer (NSCLC) and solid tumor (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Incidence and characteristics of Adverse Events and Serious Adverse Events, Incidence of Dose Limiting Toxicities at 21 days and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
recombinant L-IFN adenovirus
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT07793500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793500.